A Phase 3, Randomized, Observer-Blind, Active-Controlled Study to Compare the Immunogenicity of the booster dose of S-268019 to the COMIRNATY intramuscular injection in participants aged 5 to 11 years (COVID-19)

Shionogi & Co., Ltd.0 个研究点目标入组 100 人开始时间: 待定最近更新: 2023年8月2日

试验速览

暂无简介。

•Participant aged 5 to 11 years, at the time of signing the informed consent form (ICF).
•Male and female.
•Capable of giving signed ICF from parent(s) or legal guardian of participant and obtained assent from participant, as stated in the protocol which includes compliance with the requirements and restrictions listed in the ICF/informed assent form (IA) and in the protocol.

•Tested positive SARS-CoV-2 infection (as determined by SARS-CoV-2 antigen test) at Screening.
•Determined in the interview prior to the study intervention to have a history of SARS-CoV-2 infection.
•Receiving anticoagulation therapy, or having thrombocytopenia or coagulopathy.
•Current history of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or confound data interpretation.
•Immunosuppressed (immunocompromised, having acquired immunodeficiency syndrome [AIDS], having received steroids and having received systemic immunosuppressants within 6 months prior to the first dose of study intervention, being treated for malignant tumors, being on other immunosuppressive therapy).
•Individuals considered to have hypersensitivity to any of the study interventions or components thereof, or drug or other allergy that, in the opinion of the investigator or subinvestigator, contraindicates participation in the study (except for pollinosis and atopic dermatitis).
•Participant has a contraindication to intramuscular(IM) injections or blood draws.
•Participant weighing under 10 kg.

GMT and seroresponse rate of SARS-CoV-2 neutralizing antibody titer on Day 29

未报告次要终点

发起方